Detailed Information

Cited 0 time in webofscience Cited 9 time in scopus
Metadata Downloads

Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects

Authors
Hwang, In GyuKang, Jung HunOh, Sung YongLee, SueeKim, Sung-HyunSong, Ki-HoonSon, ChoonheePark, Min JaeKang, Myung HeeKim, Hoon GuLee, JeeyunPark, Young SukSun, Jong MuKim, Hyun JungKim, Chan KyuYi, Seong YoonJang, Joung-SoonPark, KeunchilKim, Hyo-Jin
Issue Date
Jan-2016
Publisher
Springer Verlag
Keywords
Erlotinib; Skin reaction; Epidermal growth factor; Ointment
Citation
Supportive Care in Cancer, v.24, no.1, pp 301 - 309
Pages
9
Journal Title
Supportive Care in Cancer
Volume
24
Number
1
Start Page
301
End Page
309
URI
https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/9509
DOI
10.1007/s00520-015-2783-9
ISSN
0941-4355
1433-7339
Abstract
The efficacy of erlotinib, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated in patients with non-small cell lung cancer (NSCLC) and pancreatic cancer (PC). In the present study, we evaluated the effect of epidermal growth factor (EGF) ointment on erlotinib-related skin effects (ERSEs). This was an open-label, non-comparative, multicenter, phase II trial. The patients included those diagnosed with NSCLC or PC who were treated with erlotinib. The effectiveness of the ointment was defined as follows: (1) grade 2, 3, or 4 ERSEs downgraded to a parts per thousand currency signgrade 1 or (2) grade 3 or 4 ERSEs downgraded to grade 2 and persisted for at least 2 weeks. Fifty-two patients from seven institutes in Korea were enrolled with informed consent. The final assessment included 46 patients (30 males, 16 females). According to the definition of effectiveness, the EGF ointment was effective in 36 (69.2 %) intention to treat patients. There were no statistically significant differences in the effectiveness of the EGF ointment by gender (p = 0.465), age (p = 0.547), tumor type (p = 0.085), erlotinib dosage (p = 0.117), and number of prior chemotherapy sessions (p = 0.547). The grading for the average National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) rating of rash/acne and itching improved from 2.02 +/- A 0.83 to 1.13 +/- A 0.89 and 1.52 +/- A 0.84 to 0.67 +/- A 0.90, respectively (p < 0.001). The most common reason for discontinuing the study was progression of cancer (37 %). Based on the results, the EGF ointment is effective for ERSEs, regardless of gender, age, type of tumor, and dosage of erlotinib. The EGF ointment evenly improved all kinds of symptoms of ERSEs. ClinicalTrials.gov identifier: NCT01593995.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Internal Medicine > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Chan kyu photo

Kim, Chan kyu
College of Medicine (Department of Internal Medicine)
Read more

Altmetrics

Total Views & Downloads

BROWSE